Molecular Diagnostics of the Involvement of Visually Normal Mucosa in the Malignancy Process in Urothelial Bladder Cancer

被引:0
|
作者
Bogush, T. A. [1 ]
Basharina, A. A. [1 ]
Safarov, Z. M. [1 ]
Mizaeva, I. E. [1 ]
Grishanina, A. N. [1 ]
Bogush, E. A. [2 ]
Gridneva, Ya, V [1 ]
Volkova, M., I [1 ]
Matveev, V. B. [1 ]
Kosorukov, V. S. [1 ]
机构
[1] Minist Hlth Russian Federat, Blokhin Natl Med Res Ctr Oncol, Moscow 115478, Russia
[2] Sechenov First Moscow State Med Univ, Minist Hlth Russian Federat, Moscow 119991, Russia
关键词
bladder cancer; beta III-tubulin; flow cytometry; bladder mucosa; prognosis; TUBULIN; EXPRESSION; RESISTANCE; CELLS;
D O I
10.1134/S0026893322040033
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunofluorescent method by flow cytometry was used to quantify the expression of the tumor-associated protein beta III-tubulin (TUBB3) in the tissue of urothelial bladder cancer and visually normal mucosa (56 samples in total). The expression of the marker was detected in 100% of cases, and heterogeneity of the TUBB3 expression level both in tumor tissue and in "normal" mucosa was revealed. The level of TUBB3 in the "normal" mucosa did not depend on the distance from the tumor (1 cm or more than 3 cm) and, on average, it was lower than in the tumor tissue (21.8 +/- 10.8% and 24.9 +/- 13.2% vs 35.2 +/- 12.4%; p = 0.04 and 0.005, respectively). An increase of the TUBB3 expression in the tumor and in the "normal" mucosa was revealed in muscle invasive bladder cancer compared to non-muscle invasive bladder cancer. Therefore, in urothelial bladder cancer, the tumor-associated protein TUBB3 is a molecular marker of bladder mucosa involvement in the malignancy process and predicts the risk of tumor muscle invasion, which may influence indications for early cystectomy.
引用
收藏
页码:592 / 599
页数:8
相关论文
共 50 条
  • [1] Molecular Diagnostics of the Involvement of Visually Normal Mucosa in the Malignancy Process in Urothelial Bladder Cancer
    T. A. Bogush
    A. A. Basharina
    Z. M. Safarov
    I. E. Mizaeva
    A. N. Grishanina
    E. A. Bogush
    Ya. V. Gridneva
    M. I. Volkova
    V. B. Matveev
    V. S. Kosorukov
    Molecular Biology, 2022, 56 : 592 - 599
  • [2] Molecular and immunological indicators of biological malignancy in urothelial bladder cancer
    Jozwicki, Wojciech
    Grzanka, Dariusz
    Brozyna, Anna A.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S42 - S42
  • [3] Perspectives for molecular diagnostics exemplified by urothelial bladder carcinoma
    Grimm, MO
    Burchardt, M
    Schulz, WA
    UROLOGE A, 2003, 42 (05): : 650 - +
  • [4] PLOIDY DISTURBANCE OF NORMAL-APPEARING BLADDER MUCOSA IN PATIENTS WITH UROTHELIAL CANCER - RELATIONSHIP TO MORPHOLOGY
    FARSUND, T
    LAERUM, OD
    HOSTMARK, J
    JOURNAL OF UROLOGY, 1983, 130 (06): : 1076 - 1082
  • [5] Molecular biomarkers in urothelial bladder cancer
    Kim, Wun-Jae
    Bae, Suk-Chul
    CANCER SCIENCE, 2008, 99 (04): : 646 - 652
  • [6] Molecular pathogenesis of urothelial bladder cancer
    Theodorescu, D
    HISTOLOGY AND HISTOPATHOLOGY, 2003, 18 (01) : 259 - 274
  • [7] Molecular markers in the diagnostics and therapy of urothelial cancer
    Protzel, C.
    Hakenberg, O. W.
    UROLOGE, 2010, 49 (11): : 1415 - 1423
  • [8] Molecular Pathogenesis and Diagnostics of Bladder Cancer
    Mitra, Anirban P.
    Cote, Richard J.
    ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 : 251 - 285
  • [9] The use of molecular diagnostics in bladder cancer
    Han, M
    Schoenberg, MP
    UROLOGIC ONCOLOGY, 2000, 5 (03): : 87 - 92
  • [10] Expression of RCAS1 Correlates with Urothelial Bladder Cancer Malignancy
    Jozwicki, Wojciech
    Brozyna, Anna A.
    Siekiera, Jerzy
    Slominski, Andrzej T.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (02) : 3783 - 3803